Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma
Identifieur interne : 003470 ( Istex/Corpus ); précédent : 003469; suivant : 003471Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma
Auteurs : Yuan Yang ; Yun Zhou ; Ming Lu ; Yu An ; Rui Li ; Yao Chen ; Da-Ru Lu ; Li Jin ; Wei-Ping Zhou ; Ji Qian ; Hong-Yang WangSource :
- Molecular Carcinogenesis [ 0899-1987 ] ; 2012-07.
Abstract
Human fibroblast growth factor receptor 4 (FGFR4) polymorphisms have recently been shown to be associated with tumor progression of various types of cancer, including cancer of the breast, colon, and prostate and sarcoma. However, their association with hepatocellular carcinoma (HCC) is unknown. We evaluated the association of FGFR4 polymorphisms with risk of HCC in a study population with HCC and with/without hepatitis B virus (HBV) infection in East China. We genotyped four FGFR4 SNPs (rs351855, rs641101, rs376618, and rs31777) in 1,451 Chinese subjects, including 711 patients with HCC, 368 controls with HBV infection and 372 controls without HBV infection, using the TaqMan genotyping assay. Unconditional logistic regression analysis was performed to evaluate associations of genotypes of each SNP with HCC risk. For the rs351855 (Arg388) locus, we observed a reduced HCC risk associated with the T variant genotypes, particularly for those whose tumors with gross portal vein tumor thrombosis (gross PVTT) (OR = 0.66; 95% confidence interval, 95% CI = 0.46–0.95 for CT + TT). Such a protective effect was also observed for those with liver cirrhosis (OR = 0.42; 95% CI = 0.20–0.88 for CT + TT). Clearly the T allele was associated with these conditions. Our findings suggest that genetic polymorphism in FGFR4 may be a marker for risk of HCC with liver cirrhosis and gross PVTT in Chinese populations. © 2011 Wiley Periodicals, Inc.
Url:
DOI: 10.1002/mc.20805
Links to Exploration step
ISTEX:70CE27BD37AA780025ECFE500280BFE7ED222B6CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma</title><author><name sortKey="Yang, Yuan" sort="Yang, Yuan" uniqKey="Yang Y" first="Yuan" last="Yang">Yuan Yang</name><affiliation><mods:affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Zhou, Yun" sort="Zhou, Yun" uniqKey="Zhou Y" first="Yun" last="Zhou">Yun Zhou</name><affiliation><mods:affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Lu, Ming" sort="Lu, Ming" uniqKey="Lu M" first="Ming" last="Lu">Ming Lu</name><affiliation><mods:affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</mods:affiliation></affiliation><affiliation><mods:affiliation>Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="An, Yu" sort="An, Yu" uniqKey="An Y" first="Yu" last="An">Yu An</name><affiliation><mods:affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Li, Rui" sort="Li, Rui" uniqKey="Li R" first="Rui" last="Li">Rui Li</name><affiliation><mods:affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Chen, Yao" sort="Chen, Yao" uniqKey="Chen Y" first="Yao" last="Chen">Yao Chen</name><affiliation><mods:affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Lu, Da U" sort="Lu, Da U" uniqKey="Lu D" first="Da-Ru" last="Lu">Da-Ru Lu</name><affiliation><mods:affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Jin, Li" sort="Jin, Li" uniqKey="Jin L" first="Li" last="Jin">Li Jin</name><affiliation><mods:affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Zhou, Wei Ing" sort="Zhou, Wei Ing" uniqKey="Zhou W" first="Wei-Ping" last="Zhou">Wei-Ping Zhou</name><affiliation><mods:affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Qian, Ji" sort="Qian, Ji" uniqKey="Qian J" first="Ji" last="Qian">Ji Qian</name><affiliation><mods:affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</mods:affiliation></affiliation><affiliation><mods:affiliation>Ji Qian, 220 HanDan Road, 200433 Shanghai, P. R. China.Hong‐Yang Wang, 225 Changhai Street, 200438 Shanghai, P. R. China.</mods:affiliation></affiliation></author><author><name sortKey="Wang, Hong Ang" sort="Wang, Hong Ang" uniqKey="Wang H" first="Hong-Yang" last="Wang">Hong-Yang Wang</name><affiliation><mods:affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</mods:affiliation></affiliation><affiliation><mods:affiliation>Ji Qian, 220 HanDan Road, 200433 Shanghai, P. R. China.Hong‐Yang Wang, 225 Changhai Street, 200438 Shanghai, P. R. China.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:70CE27BD37AA780025ECFE500280BFE7ED222B6C</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1002/mc.20805</idno><idno type="url">https://api.istex.fr/document/70CE27BD37AA780025ECFE500280BFE7ED222B6C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003470</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">003470</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma<ref type="note" target="#fn1"></ref><ref type="note" target="#fn2"></ref></title><author><name sortKey="Yang, Yuan" sort="Yang, Yuan" uniqKey="Yang Y" first="Yuan" last="Yang">Yuan Yang</name><affiliation><mods:affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Zhou, Yun" sort="Zhou, Yun" uniqKey="Zhou Y" first="Yun" last="Zhou">Yun Zhou</name><affiliation><mods:affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Lu, Ming" sort="Lu, Ming" uniqKey="Lu M" first="Ming" last="Lu">Ming Lu</name><affiliation><mods:affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</mods:affiliation></affiliation><affiliation><mods:affiliation>Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="An, Yu" sort="An, Yu" uniqKey="An Y" first="Yu" last="An">Yu An</name><affiliation><mods:affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Li, Rui" sort="Li, Rui" uniqKey="Li R" first="Rui" last="Li">Rui Li</name><affiliation><mods:affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Chen, Yao" sort="Chen, Yao" uniqKey="Chen Y" first="Yao" last="Chen">Yao Chen</name><affiliation><mods:affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Lu, Da U" sort="Lu, Da U" uniqKey="Lu D" first="Da-Ru" last="Lu">Da-Ru Lu</name><affiliation><mods:affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Jin, Li" sort="Jin, Li" uniqKey="Jin L" first="Li" last="Jin">Li Jin</name><affiliation><mods:affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Zhou, Wei Ing" sort="Zhou, Wei Ing" uniqKey="Zhou W" first="Wei-Ping" last="Zhou">Wei-Ping Zhou</name><affiliation><mods:affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</mods:affiliation></affiliation></author><author><name sortKey="Qian, Ji" sort="Qian, Ji" uniqKey="Qian J" first="Ji" last="Qian">Ji Qian</name><affiliation><mods:affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</mods:affiliation></affiliation><affiliation><mods:affiliation>Ji Qian, 220 HanDan Road, 200433 Shanghai, P. R. China.Hong‐Yang Wang, 225 Changhai Street, 200438 Shanghai, P. R. China.</mods:affiliation></affiliation></author><author><name sortKey="Wang, Hong Ang" sort="Wang, Hong Ang" uniqKey="Wang H" first="Hong-Yang" last="Wang">Hong-Yang Wang</name><affiliation><mods:affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</mods:affiliation></affiliation><affiliation><mods:affiliation>Ji Qian, 220 HanDan Road, 200433 Shanghai, P. R. China.Hong‐Yang Wang, 225 Changhai Street, 200438 Shanghai, P. R. China.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Molecular Carcinogenesis</title><title level="j" type="alt">MOLECULAR CARCINOGENESIS</title><idno type="ISSN">0899-1987</idno><idno type="eISSN">1098-2744</idno><imprint><biblScope unit="vol">51</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="515">515</biblScope><biblScope unit="page" to="521">521</biblScope><biblScope unit="page-count">7</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-07">2012-07</date></imprint><idno type="ISSN">0899-1987</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0899-1987</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Human fibroblast growth factor receptor 4 (FGFR4) polymorphisms have recently been shown to be associated with tumor progression of various types of cancer, including cancer of the breast, colon, and prostate and sarcoma. However, their association with hepatocellular carcinoma (HCC) is unknown. We evaluated the association of FGFR4 polymorphisms with risk of HCC in a study population with HCC and with/without hepatitis B virus (HBV) infection in East China. We genotyped four FGFR4 SNPs (rs351855, rs641101, rs376618, and rs31777) in 1,451 Chinese subjects, including 711 patients with HCC, 368 controls with HBV infection and 372 controls without HBV infection, using the TaqMan genotyping assay. Unconditional logistic regression analysis was performed to evaluate associations of genotypes of each SNP with HCC risk. For the rs351855 (Arg388) locus, we observed a reduced HCC risk associated with the T variant genotypes, particularly for those whose tumors with gross portal vein tumor thrombosis (gross PVTT) (OR = 0.66; 95% confidence interval, 95% CI = 0.46–0.95 for CT + TT). Such a protective effect was also observed for those with liver cirrhosis (OR = 0.42; 95% CI = 0.20–0.88 for CT + TT). Clearly the T allele was associated with these conditions. Our findings suggest that genetic polymorphism in FGFR4 may be a marker for risk of HCC with liver cirrhosis and gross PVTT in Chinese populations. © 2011 Wiley Periodicals, Inc.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>fgfr4</json:string><json:string>polymorphism</json:string><json:string>genotype</json:string><json:string>allele</json:string><json:string>pvtt</json:string><json:string>receptor</json:string><json:string>hepatocellular</json:string><json:string>cirrhosis</json:string><json:string>broblast</json:string><json:string>gross pvtt</json:string><json:string>hepatocellular carcinoma</json:string><json:string>shanghai</json:string><json:string>carcinoma</json:string><json:string>carcinogenesis</json:string><json:string>kinase</json:string><json:string>hbsag</json:string><json:string>hepatocytes</json:string><json:string>broblast growth factor receptor</json:string><json:string>genotype allele</json:string><json:string>fgfr4 polymorphisms</json:string><json:string>drinking status</json:string><json:string>tumor progression</json:string><json:string>biol chem</json:string><json:string>liver cirrhosis</json:string><json:string>bile acids</json:string><json:string>molecular carcinogenesis</json:string><json:string>study population</json:string><json:string>fgfr4 snps</json:string><json:string>fgfr4 gene</json:string><json:string>progression</json:string><json:string>susceptibility</json:string><json:string>broblast growth factor</json:string><json:string>bile acid synthesis</json:string><json:string>genetic polymorphisms</json:string><json:string>fibroblast growth factor receptor</json:string><json:string>variant genotypes</json:string><json:string>regression analysis</json:string><json:string>genotype frequencies</json:string><json:string>risk factors</json:string><json:string>east china area</json:string><json:string>bile</json:string><json:string>prostate</json:string><json:string>wiley periodicals</json:string><json:string>mature hepatocytes</json:string><json:string>liver mass</json:string><json:string>protective effect</json:string><json:string>gross portal vein tumor thrombosis</json:string><json:string>bile acid pool</json:string><json:string>bile acid biosynthesis</json:string><json:string>clinical course</json:string><json:string>tumor cells</json:string><json:string>present study</json:string><json:string>cell growth</json:string><json:string>main portal vein</json:string><json:string>tumor metastasis</json:string><json:string>cigarette smoking</json:string><json:string>family history</json:string><json:string>dbsnp database</json:string><json:string>critical role</json:string><json:string>liver functions</json:string><json:string>eastern hepatobiliary surgery hospital</json:string><json:string>fgfr4 variations</json:string><json:string>other hand</json:string><json:string>surface antigen</json:string><json:string>genetic polymorphism</json:string><json:string>lower risk</json:string><json:string>homozygous genotype</json:string><json:string>logistic regression analysis</json:string><json:string>enterohepatic circulation</json:string><json:string>tumor growth</json:string><json:string>bile acid pool size</json:string><json:string>lower frequency</json:string><json:string>many patients</json:string><json:string>surgical treatment</json:string><json:string>bladder cancer</json:string><json:string>fgfr kinases</json:string><json:string>odds ratio</json:string></teeft></keywords><author><json:item><name>Yuan Yang</name><affiliations><json:string>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</json:string></affiliations></json:item><json:item><name>Yun Zhou</name><affiliations><json:string>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</json:string></affiliations></json:item><json:item><name>Ming Lu</name><affiliations><json:string>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</json:string><json:string>Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, P. R. China</json:string></affiliations></json:item><json:item><name>Yu An</name><affiliations><json:string>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</json:string></affiliations></json:item><json:item><name>Rui Li</name><affiliations><json:string>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</json:string></affiliations></json:item><json:item><name>Yao Chen</name><affiliations><json:string>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</json:string></affiliations></json:item><json:item><name>Da‐Ru Lu</name><affiliations><json:string>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</json:string></affiliations></json:item><json:item><name>Li Jin</name><affiliations><json:string>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</json:string></affiliations></json:item><json:item><name>Wei‐Ping Zhou</name><affiliations><json:string>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</json:string></affiliations></json:item><json:item><name>Ji Qian</name><affiliations><json:string>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</json:string><json:string>Ji Qian, 220 HanDan Road, 200433 Shanghai, P. R. China.Hong‐Yang Wang, 225 Changhai Street, 200438 Shanghai, P. R. China.</json:string></affiliations></json:item><json:item><name>Hong‐Yang Wang</name><affiliations><json:string>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</json:string><json:string>Ji Qian, 220 HanDan Road, 200433 Shanghai, P. R. China.Hong‐Yang Wang, 225 Changhai Street, 200438 Shanghai, P. R. China.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>fibroblast growth factor receptor 4</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>hepatocellular carcinoma</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>genotyping</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>association study</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>genetic variant</value></json:item></subject><articleId><json:string>MC20805</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Human fibroblast growth factor receptor 4 (FGFR4) polymorphisms have recently been shown to be associated with tumor progression of various types of cancer, including cancer of the breast, colon, and prostate and sarcoma. However, their association with hepatocellular carcinoma (HCC) is unknown. We evaluated the association of FGFR4 polymorphisms with risk of HCC in a study population with HCC and with/without hepatitis B virus (HBV) infection in East China. We genotyped four FGFR4 SNPs (rs351855, rs641101, rs376618, and rs31777) in 1,451 Chinese subjects, including 711 patients with HCC, 368 controls with HBV infection and 372 controls without HBV infection, using the TaqMan genotyping assay. Unconditional logistic regression analysis was performed to evaluate associations of genotypes of each SNP with HCC risk. For the rs351855 (Arg388) locus, we observed a reduced HCC risk associated with the T variant genotypes, particularly for those whose tumors with gross portal vein tumor thrombosis (gross PVTT) (OR = 0.66; 95% confidence interval, 95% CI = 0.46–0.95 for CT + TT). Such a protective effect was also observed for those with liver cirrhosis (OR = 0.42; 95% CI = 0.20–0.88 for CT + TT). Clearly the T allele was associated with these conditions. Our findings suggest that genetic polymorphism in FGFR4 may be a marker for risk of HCC with liver cirrhosis and gross PVTT in Chinese populations. © 2011 Wiley Periodicals, Inc.</abstract><qualityIndicators><score>6.636</score><pdfVersion>1.3</pdfVersion><pdfPageSize>648 x 864 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1445</abstractCharCount><pdfWordCount>4056</pdfWordCount><pdfCharCount>27645</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>215</abstractWordCount></qualityIndicators><title>Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma</title><genre><json:string>article</json:string></genre><host><title>Molecular Carcinogenesis</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1098-2744</json:string></doi><issn><json:string>0899-1987</json:string></issn><eissn><json:string>1098-2744</json:string></eissn><publisherId><json:string>MC</json:string></publisherId><volume>51</volume><issue>7</issue><pages><first>515</first><last>521</last><total>7</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Research Article</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>oncology</json:string><json:string>biochemistry & molecular biology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>oncology & carcinogenesis</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string><json:string>techniques d'exploration et de diagnostic (generalites)</json:string></inist></categories><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><doi><json:string>10.1002/mc.20805</json:string></doi><id>70CE27BD37AA780025ECFE500280BFE7ED222B6C</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/70CE27BD37AA780025ECFE500280BFE7ED222B6C/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/70CE27BD37AA780025ECFE500280BFE7ED222B6C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/70CE27BD37AA780025ECFE500280BFE7ED222B6C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma<ref type="note" target="#fn1"></ref><ref type="note" target="#fn2"></ref></title></titleStmt><publicationStmt><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><licence>Copyright © 2011 Wiley Periodicals, Inc.</licence></availability><date type="published" when="2012-07"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma<ref type="note" target="#fn1"></ref><ref type="note" target="#fn2"></ref></title><title level="a" type="short" xml:lang="en">FGFR4 POLYMORPHISMS AND RISK OF HCC PROGRESSION</title><author xml:id="author-0000"><persName><forename type="first">Yuan</forename><surname>Yang</surname></persName><affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China<address><country key="CN"></country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Yun</forename><surname>Zhou</surname></persName><affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China<address><country key="CN"></country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Ming</forename><surname>Lu</surname></persName><affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China<address><country key="CN"></country></address></affiliation><affiliation>Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, P. R. China<address><country key="CN"></country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Yu</forename><surname>An</surname></persName><affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China<address><country key="CN"></country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Rui</forename><surname>Li</surname></persName><affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China<address><country key="CN"></country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Yao</forename><surname>Chen</surname></persName><affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China<address><country key="CN"></country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Da‐Ru</forename><surname>Lu</surname></persName><affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China<address><country key="CN"></country></address></affiliation></author><author xml:id="author-0007"><persName><forename type="first">Li</forename><surname>Jin</surname></persName><affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China<address><country key="CN"></country></address></affiliation></author><author xml:id="author-0008"><persName><forename type="first">Wei‐Ping</forename><surname>Zhou</surname></persName><affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China<address><country key="CN"></country></address></affiliation></author><author xml:id="author-0009" role="corresp"><persName><forename type="first">Ji</forename><surname>Qian</surname></persName><affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China<address><country key="CN"></country></address></affiliation><affiliation>Ji Qian, 220 HanDan Road, 200433 Shanghai, P. R. China. Hong‐Yang Wang, 225 Changhai Street, 200438 Shanghai, P. R. China.</affiliation></author><author xml:id="author-0010" role="corresp"><persName><forename type="first">Hong‐Yang</forename><surname>Wang</surname></persName><affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China<address><country key="CN"></country></address></affiliation><affiliation>Ji Qian, 220 HanDan Road, 200433 Shanghai, P. R. China. Hong‐Yang Wang, 225 Changhai Street, 200438 Shanghai, P. R. China.</affiliation></author><idno type="istex">70CE27BD37AA780025ECFE500280BFE7ED222B6C</idno><idno type="DOI">10.1002/mc.20805</idno><idno type="unit">MC20805</idno><idno type="toTypesetVersion">file:MC.MC20805.pdf</idno></analytic><monogr><title level="j" type="main">Molecular Carcinogenesis</title><title level="j" type="alt">MOLECULAR CARCINOGENESIS</title><idno type="pISSN">0899-1987</idno><idno type="eISSN">1098-2744</idno><idno type="book-DOI">10.1002/(ISSN)1098-2744</idno><idno type="book-part-DOI">10.1002/mc.v51.7</idno><idno type="product">MC</idno><imprint><biblScope unit="vol">51</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="515">515</biblScope><biblScope unit="page" to="521">521</biblScope><biblScope unit="page-count">7</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-07"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>Human fibroblast growth factor receptor 4 (<hi rend="italic">FGFR4</hi>) polymorphisms have recently been shown to be associated with tumor progression of various types of cancer, including cancer of the breast, colon, and prostate and sarcoma. However, their association with hepatocellular carcinoma (HCC) is unknown. We evaluated the association of <hi rend="italic">FGFR4</hi> polymorphisms with risk of HCC in a study population with HCC and with/without hepatitis B virus (HBV) infection in East China. We genotyped four <hi rend="italic">FGFR4</hi> SNPs (rs351855, rs641101, rs376618, and rs31777) in 1,451 Chinese subjects, including 711 patients with HCC, 368 controls with HBV infection and 372 controls without HBV infection, using the TaqMan genotyping assay. Unconditional logistic regression analysis was performed to evaluate associations of genotypes of each SNP with HCC risk. For the rs351855 (Arg388) locus, we observed a reduced HCC risk associated with the T variant genotypes, particularly for those whose tumors with gross portal vein tumor thrombosis (gross PVTT) (OR = 0.66; 95% confidence interval, 95% CI = 0.46–0.95 for CT + TT). Such a protective effect was also observed for those with liver cirrhosis (OR = 0.42; 95% CI = 0.20–0.88 for CT + TT). Clearly the T allele was associated with these conditions. Our findings suggest that genetic polymorphism in <hi rend="italic">FGFR4</hi> may be a marker for risk of HCC with liver cirrhosis and gross PVTT in Chinese populations. © 2011 Wiley Periodicals, Inc.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="kwd1">fibroblast growth factor receptor 4</term><term xml:id="kwd2">hepatocellular carcinoma</term><term xml:id="kwd3">genotyping</term><term xml:id="kwd4">association study</term><term xml:id="kwd5">genetic variant</term></keywords><classCode scheme="articleCategory">Research Article</classCode><classCode scheme="tocHeading1">Research Articles</classCode></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/70CE27BD37AA780025ECFE500280BFE7ED222B6C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1098-2744</doi><issn type="print">0899-1987</issn><issn type="electronic">1098-2744</issn><idGroup><id type="product" value="MC"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOLECULAR CARCINOGENESIS">Molecular Carcinogenesis</title><title type="short">Mol. Carcinog.</title></titleGroup></publicationMeta><publicationMeta level="part" position="70"><doi origin="wiley" registered="yes">10.1002/mc.v51.7</doi><numberingGroup><numbering type="journalVolume" number="51">51</numbering><numbering type="journalIssue">7</numbering></numberingGroup><coverDate startDate="2012-07">July 2012</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="10" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mc.20805</doi><idGroup><id type="unit" value="MC20805"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="publisher">Copyright © 2011 Wiley Periodicals, Inc.</copyright><eventGroup><event type="manuscriptReceived" date="2011-02-20"></event><event type="manuscriptRevised" date="2011-05-04"></event><event type="manuscriptAccepted" date="2011-05-04"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.1.5 mode:FullText" date="2012-06-04"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-06-07"></event><event type="firstOnline" date="2011-06-07"></event><event type="publishedOnlineFinalForm" date="2012-06-04"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.3.4 mode:FullText" date="2015-02-24"></event></eventGroup><numberingGroup><numbering type="pageFirst">515</numbering><numbering type="pageLast">521</numbering></numberingGroup><correspondenceTo><lineatedText><line>Ji Qian, 220 HanDan Road, 200433 Shanghai, P. R. China.</line><line>Hong‐Yang Wang, 225 Changhai Street, 200438 Shanghai, P. R. China.</line></lineatedText></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MC.MC20805.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="40"></count><count type="wordTotal" number="5350"></count></countGroup><titleGroup><title type="main" xml:lang="en">Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma<link href="#fn1"></link><link href="#fn2"></link></title><title type="short" xml:lang="en"><fi>FGFR4</fi> POLYMORPHISMS AND RISK OF HCC PROGRESSION</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Yuan</givenNames><familyName>Yang</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Yun</givenNames><familyName>Zhou</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2 #af3"><personName><givenNames>Ming</givenNames><familyName>Lu</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Yu</givenNames><familyName>An</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Rui</givenNames><familyName>Li</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Yao</givenNames><familyName>Chen</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Da‐Ru</givenNames><familyName>Lu</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Li</givenNames><familyName>Jin</familyName></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Wei‐Ping</givenNames><familyName>Zhou</familyName></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af2" corresponding="yes"><personName><givenNames>Ji</givenNames><familyName>Qian</familyName></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Hong‐Yang</givenNames><familyName>Wang</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="CN" type="organization"><unparsedAffiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="CN" type="organization"><unparsedAffiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="CN" type="organization"><unparsedAffiliation>Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, P. R. China</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">fibroblast growth factor receptor 4</keyword><keyword xml:id="kwd2">hepatocellular carcinoma</keyword><keyword xml:id="kwd3">genotyping</keyword><keyword xml:id="kwd4">association study</keyword><keyword xml:id="kwd5">genetic variant</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Human fibroblast growth factor receptor 4 (<i>FGFR4</i>) polymorphisms have recently been shown to be associated with tumor progression of various types of cancer, including cancer of the breast, colon, and prostate and sarcoma. However, their association with hepatocellular carcinoma (HCC) is unknown. We evaluated the association of <i>FGFR4</i> polymorphisms with risk of HCC in a study population with HCC and with/without hepatitis B virus (HBV) infection in East China. We genotyped four <i>FGFR4</i> SNPs (rs351855, rs641101, rs376618, and rs31777) in 1,451 Chinese subjects, including 711 patients with HCC, 368 controls with HBV infection and 372 controls without HBV infection, using the TaqMan genotyping assay. Unconditional logistic regression analysis was performed to evaluate associations of genotypes of each SNP with HCC risk. For the rs351855 (Arg388) locus, we observed a reduced HCC risk associated with the T variant genotypes, particularly for those whose tumors with gross portal vein tumor thrombosis (gross PVTT) (OR = 0.66; 95% confidence interval, 95% CI = 0.46–0.95 for CT + TT). Such a protective effect was also observed for those with liver cirrhosis (OR = 0.42; 95% CI = 0.20–0.88 for CT + TT). Clearly the T allele was associated with these conditions. Our findings suggest that genetic polymorphism in <i>FGFR4</i> may be a marker for risk of HCC with liver cirrhosis and gross PVTT in Chinese populations. © 2011 Wiley Periodicals, Inc.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Conflict of interest: There is no conflict of interest to disclose.</p></note><note xml:id="fn2"><p>Yuan Yang and Yun Zhou contributed equally to this work.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>FGFR4 POLYMORPHISMS AND RISK OF HCC PROGRESSION</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma</title></titleInfo><name type="personal"><namePart type="given">Yuan</namePart><namePart type="family">Yang</namePart><affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yun</namePart><namePart type="family">Zhou</namePart><affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ming</namePart><namePart type="family">Lu</namePart><affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</affiliation><affiliation>Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, P. R. China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yu</namePart><namePart type="family">An</namePart><affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rui</namePart><namePart type="family">Li</namePart><affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yao</namePart><namePart type="family">Chen</namePart><affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Da‐Ru</namePart><namePart type="family">Lu</namePart><affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Li</namePart><namePart type="family">Jin</namePart><affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Wei‐Ping</namePart><namePart type="family">Zhou</namePart><affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ji</namePart><namePart type="family">Qian</namePart><affiliation>State Key Laboratory of Genetic Engineering and Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, P. R. China</affiliation><affiliation>Ji Qian, 220 HanDan Road, 200433 Shanghai, P. R. China.Hong‐Yang Wang, 225 Changhai Street, 200438 Shanghai, P. R. China.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hong‐Yang</namePart><namePart type="family">Wang</namePart><affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China</affiliation><affiliation>Ji Qian, 220 HanDan Road, 200433 Shanghai, P. R. China.Hong‐Yang Wang, 225 Changhai Street, 200438 Shanghai, P. R. China.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2012-07</dateIssued><dateCaptured encoding="w3cdtf">2011-02-20</dateCaptured><dateValid encoding="w3cdtf">2011-05-04</dateValid><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">4</extent><extent unit="references">40</extent><extent unit="words">5350</extent></physicalDescription><abstract lang="en">Human fibroblast growth factor receptor 4 (FGFR4) polymorphisms have recently been shown to be associated with tumor progression of various types of cancer, including cancer of the breast, colon, and prostate and sarcoma. However, their association with hepatocellular carcinoma (HCC) is unknown. We evaluated the association of FGFR4 polymorphisms with risk of HCC in a study population with HCC and with/without hepatitis B virus (HBV) infection in East China. We genotyped four FGFR4 SNPs (rs351855, rs641101, rs376618, and rs31777) in 1,451 Chinese subjects, including 711 patients with HCC, 368 controls with HBV infection and 372 controls without HBV infection, using the TaqMan genotyping assay. Unconditional logistic regression analysis was performed to evaluate associations of genotypes of each SNP with HCC risk. For the rs351855 (Arg388) locus, we observed a reduced HCC risk associated with the T variant genotypes, particularly for those whose tumors with gross portal vein tumor thrombosis (gross PVTT) (OR = 0.66; 95% confidence interval, 95% CI = 0.46–0.95 for CT + TT). Such a protective effect was also observed for those with liver cirrhosis (OR = 0.42; 95% CI = 0.20–0.88 for CT + TT). Clearly the T allele was associated with these conditions. Our findings suggest that genetic polymorphism in FGFR4 may be a marker for risk of HCC with liver cirrhosis and gross PVTT in Chinese populations. © 2011 Wiley Periodicals, Inc.</abstract><note type="content">*Conflict of interest: There is no conflict of interest to disclose.</note><note type="content">*Yuan Yang and Yun Zhou contributed equally to this work.</note><subject lang="en"><genre>keywords</genre><topic>fibroblast growth factor receptor 4</topic><topic>hepatocellular carcinoma</topic><topic>genotyping</topic><topic>association study</topic><topic>genetic variant</topic></subject><relatedItem type="host"><titleInfo><title>Molecular Carcinogenesis</title></titleInfo><titleInfo type="abbreviated"><title>Mol. Carcinog.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0899-1987</identifier><identifier type="eISSN">1098-2744</identifier><identifier type="DOI">10.1002/(ISSN)1098-2744</identifier><identifier type="PublisherID">MC</identifier><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>515</start><end>521</end><total>7</total></extent></part></relatedItem><identifier type="istex">70CE27BD37AA780025ECFE500280BFE7ED222B6C</identifier><identifier type="DOI">10.1002/mc.20805</identifier><identifier type="ArticleID">MC20805</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Wiley Periodicals, Inc.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003470 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003470 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:70CE27BD37AA780025ECFE500280BFE7ED222B6C
|texte= Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma
}}
| This area was generated with Dilib version V0.6.31. |  |